Development of a Peptidomic Rapid Point-of-Care TB Diagnostic

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$524,856.00
Award Year:
2010
Program:
STTR
Phase:
Phase I
Contract:
1R41AI091049-01
Award Id:
n/a
Agency Tracking Number:
R41AI091049
Solicitation Year:
2010
Solicitation Topic Code:
NIAID
Solicitation Number:
PA09-116
Small Business Information
242 E 33RD ST, NEW YORK, NY, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
Y
Duns:
826051687
Principal Investigator:
R. NIEDBALA
(610) 597-5501
san204@lehigh.edu
Business Contact:
WILLIAM ABRAMS
(212) 998-9241
william.abrams@nyu.edu
Research Institution:
New York University

OFFICE OF SPONSORED PROGRAMS
NEW YORK, NY, 10012-2331
() -
Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): The goals of this proposal are to devise rapid serological tests that can replace the sputum smear test for the diagnosis of active TB and meets the WHO specifications to replace microscopy in resource-limited countriesbased on immunodominant peptides from three M. tb cell-wall proteins. Although direct smear microscopy is highly specific, the test is tedious, time-consuming, requires multiple patient visits before diagnosis, and has limited sensitivity. The Company's approach is based on the prior identification of three cell wall proteins of M. tuberculosis (PTRP, PE-PGRS51 and LipC) that are highly immunogenic in TB subjects, but not in individuals with latent TB infection (LTBI). The identified immunodominant epitopes were mapped and combinations of immunodominant peptides derived from these proteins are predicted to detect gt95% of smear positive TB patients. Specifically we plan to devise microplate ELISA assay(s) based on the peptide combinations demonstrating maximum sensitivity and specificity for detection of anti- TB antibodies in sera, and to verify the performance of the assays with a panel of sera from cohorts of TB-negative subjects (Aim #1); to translate the microplate ELISA assay to a lateral flow point-of- care format using the 9 immunodominant individual peptides previously identified (Aim #2); and to identify the best peptide combination(s) to use in a multiplexed lateral flow device to result in maximum sensitivity and specificity. This assay will be validated with large-panels of clinical samples (Aim #3). During Phase 2, we plan to further validate and refine the rapid test with samples from diverse geographic sites and advance commercialization of both the microplate and rapid lateral flow assays. Testing will be performed with both serum and oral fluids samples. This will allow the Company to determine if it is necessary to have region-specific tests or if one combinatorial test is appropriate worldwide. The development of a non-invasive salivary and/or serum diagnostic test for active TB will fill an urgent need in resource-limited areas. PUBLIC HEALTH RELEVANCE: The work proposed will ultimately lead to development of an inexpensive, robust, and rapid diagnostic ELISA test and point-of-care device for active TB infections. No reliable rapid test for TB currently exists and this assay would represent a major advance.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government